158 related articles for article (PubMed ID: 11156527)
1. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
Roh H; Pippin J; Boswell C; Drebin JA
J Surg Res; 1998 Jun; 77(1):85-90. PubMed ID: 9698539
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.
Roh H; Pippin J; Drebin JA
Cancer Res; 2000 Feb; 60(3):560-5. PubMed ID: 10676637
[TBL] [Abstract][Full Text] [Related]
4. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
[TBL] [Abstract][Full Text] [Related]
6. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
[TBL] [Abstract][Full Text] [Related]
8. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
Tuna M; Chavez-Reyes A; Tari AM
Oncogene; 2005 Feb; 24(9):1648-52. PubMed ID: 15674342
[TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents.
Roh H; Hirose CB; Boswell CB; Pippin JA; Drebin JA
Surgery; 1999 Aug; 126(2):413-21. PubMed ID: 10455915
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
11. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
12. Targeting human breast cancer cells that overexpress HER-2/neu mRNA by an antisense iron responsive element.
Yan DH
Biochem Biophys Res Commun; 1998 May; 246(2):353-8. PubMed ID: 9610362
[TBL] [Abstract][Full Text] [Related]
13. Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy.
Chuang TC; Liu JY; Lin CT; Tang YT; Yeh MH; Chang SC; Li JW; Kao MC
FEBS Lett; 2007 Sep; 581(23):4443-9. PubMed ID: 17719580
[TBL] [Abstract][Full Text] [Related]
14. SV40 T/t-common polypeptide specifically induces apoptosis in human cancer cells that overexpress HER2/neu.
Wen CC; Cheng SA; Hsuen SP; Huang YL; Kuo ZK; Lee HF; Kuo CH; Du JL; Wang WB
Cancer Res; 2006 Jun; 66(11):5847-57. PubMed ID: 16740724
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
16. [Geldanamycin inhibits proliferation and motility of human HER2/neu-overexpressing breast cancer cell line SKBr3].
Wang K; Ma QY; Ren Y; He JJ; Chen WK
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1480-4. PubMed ID: 17959518
[TBL] [Abstract][Full Text] [Related]
17. Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission.
Schiffer IB; Gebhard S; Heimerdinger CK; Heling A; Hast J; Wollscheid U; Seliger B; Tanner B; Gilbert S; Beckers T; Baasner S; Brenner W; Spangenberg C; Prawitt D; Trost T; Schreiber WG; Zabel B; Thelen M; Lehr HA; Oesch F; Hengstler JG
Cancer Res; 2003 Nov; 63(21):7221-31. PubMed ID: 14612517
[TBL] [Abstract][Full Text] [Related]
18. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells.
Spänkuch-Schmitt B; Wolf G; Solbach C; Loibl S; Knecht R; Stegmüller M; von Minckwitz G; Kaufmann M; Strebhardt K
Oncogene; 2002 May; 21(20):3162-71. PubMed ID: 12082631
[TBL] [Abstract][Full Text] [Related]
20. Soy isoflavone genistein modulates cell cycle progression and induces apoptosis in HER-2/neu oncogene expressing human breast epithelial cells.
Katdare M; Osborne M; Telang NT
Int J Oncol; 2002 Oct; 21(4):809-15. PubMed ID: 12239620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
